Article
Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
All News
Article
A nationwide population-based study, by Beydon et al. (OP0044), has performed a more recent (2010-2020) analysis of cancer incidence in people living with RA within the French national claim database, compared to general population, measured in the French Network of Population-Based Cancer Registries.
Article
The use of artificial intelligence to analyse large data sets using its subset component machine learning has taken centre stage recently in the management of rheumatic conditions, including rheumatoid arthritis. The use of AI is now starting to cross the various stages in patient care from detection, diagnosis, treatment and the prediction of long-term outcome.
Janet Pope
Tweet
What is the course of clinically suspect arthralgia in CCP+ vs neg? 781 pts, 136 got RA and sl more resolved symptoms. RA developed in both groups ACPA+ develop more rapidly - if resolution, still more MRI + vs neg. #EULAR2023 POS319 @RheumNow Diff patterns of progression
Aurelie Najm
Tweet
Weather impacts outcomes in RA: myth or reality? ⛈🌦
Larger study to date 14200 weather-matched PROs
Mean PtP PtF PtGA scores higher in winter
Few meteorological measures significantly correlated w/ PROs, but correlations are weak
@RheumNow #EULAR23 POS0325 https://t.co/7AJmbLQrPW
Aurelie Najm
Tweet
REMOTRA; REMote moniToring in pReclinical Arthritis
43pts CSA 6 Mo follow up
Pts acceptance and usage decrease during time (like many other studies using apps)
Composite score of PROs asso w/ risk of RA (...but VPP 12%)
Digital follow up of Pre-RA is not ready for clinic yet. https://t.co/o31dVEa5xt
David Liew
Tweet
Amazing the chatter in the room for this one. The idea that a new JAKi might genuinely outperform existing JAKi in hard-to-treat RA, without safety cost, is particularly enticing.
We all want to see the paper & healthy skepticism of ph2, but watch this space #EULAR2023 @RheumNow https://t.co/jEyk8zqZN8
Janet Pope
Tweet
A mono therapy study RCT of TLL-018 vs #Tofa in RA subanalyses of previous JAKi exposure have not been done. Pts could have failed #Tofacitinib & enrolled so data could be divided to determine how this group responded. Safety looked good in both Rx LB0001 @RheumNow #EULAR2023 https://t.co/4kBHxWmk0q
Janet Pope
Tweet
What about a new oral drug in active #rheumatoid #arthritis vs #JAKi #Tofacitinib? TLL-018 a potent JAK1/TYK2 inhibitor was compared with #Tofa and dose ranging of 10, 20, 30 mg of TLL-018 and many Pts w past TNFi and w JAKi. High dose won #EULAR2023 @RheumNow @eular_org LB0001 https://t.co/UXhT7LV1oD
David Liew
Tweet
The key data for treating clinically suspect arthralgias (CSA):
TREAT-EARLIER (MTX)
ARIAA, APIPPRA (abatacept)
but what we need to do going forward:
stratify pts better for studies
predict individual risk better, to weight up risk-benefit of intervention
#EULAR2023 @RheumNow https://t.co/h3gNIyLxPY
David Liew
Tweet
Key arguments for CSA skeptics:
- definitions, imaging aren’t anywhere near as good as our own suspicion as clinicians is
- we still struggle to prevent RA
- it’s easy to go down a therapeutic slippery slope, and hard to track back
- labels are hard to remove
#EULAR2023 @RheumNow https://t.co/4adop3IR8g
Dr. John Cush
Tweet
ILD in RA and PsA
@AurelieRheumo discusses inconsistent data inconsistent data have proposed on the effect of bio/tsDMARDs on the risk of ILD.
ILD is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis.
https://t.co/U1RjvgTCL8 https://t.co/qmxXBTK05N
Dr. John Cush
Tweet
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Janet Pope
Tweet
Clinically suspect arthralgia-what is needed are predictors that enrich WHO will develop RA. Otherwise in 85% of Pts your (sham) Rx will work. If we need to reset the immune response- early makes sense but many will NOT have #RA over the next few yrs. @RheumNow #EULAR2023 https://t.co/vDv6cHqFUn
Janet Pope
Tweet
#Clinically suspect #arthralgia debate BE CAREFUL how you apply the criteria as sensitivity / specificity will vary if low pretest likelihood. @eular_org @RheumNow https://t.co/2XAwXbp1fi
Janet Pope
Tweet
#ClinicalPearls #rheumatoid #arthritis is changing. Less extra articulation and less mortality except ILD. Legacy pts exposed to ASA high dose, NSAIDs and injectable gold. We still see it rarely. @RheumNow #EULAR2023 @eular_org https://t.co/sC8vZkjO2x https://t.co/BFdpubei4u
Janet Pope
Tweet
Debate @ #EULAR2023 @eular_org about clinically suspect arthralgia. Myth or just #rheumatoid #arthritis in the making? https://t.co/Kj4CeE3NtU
Aurelie Najm
Tweet
Did you know?
Painter Peter Paul Rubens had Rheumatoid Arthritis as demonstrated in swellings and deformities observed in this self-portrait
An image I often use in my teaching to student of clinical aspects of RA
#rheumatologyandart #teachingpearls
#EULAR23 @RheumNow https://t.co/xwDisTUHdy
Dr. Antoni Chan
Tweet
Herpes Zoster vaccination in RA patients treated with Upadacitinib and MTX showed a satisfactory response,
slight reduction in response compared to general population in both antibody and cell mediated responses Winthrop K, Abst#OP0225 #EULAR2023 @RheumNow https://t.co/wxwbOYsn5K
Aurelie Najm
Tweet
Let le introduce you to ARTHUR 🤖
A very skilled robot who scans your hands and wrists in 15 mn 🤚
Amazing to see new #AI developments that will make our lifes’ easier!
#EULAR23 @ROPCA3 @JustSoren Stand M6
@RheumNow https://t.co/7PtR2CGqTt
